Feb 27,2024

These diabetes devices are set to launch in 2024

In 2024, the diabetes technology landscape is poised for significant advancements with several major product launches. Medtronic introduces its MiniMed 780G automated insulin delivery system, featuring the Simplera Sync sensor, set for a phased commercial launch in Europe in the summer. Dexcom anticipates the launch of its Stelo glucose monitor designed for non-insulin users in the U.S. during the summer, offering a 15-day wear with a unique software experience. Insulet plans to release its Omnipod GO long-acting insulin delivery system for type 2 diabetes in 2024. Tandem Diabetes Care has already launched its Mobi insulin patch pump, a durable automated insulin delivery system. Dexcom has introduced Dexcom ONE+ in Europe, utilizing the G7 sensor and providing real-time continuous glucose monitoring. Additionally, notable integrations include Insulet Omnipod 5 with Dexcom's G7 and Abbott's FreeStyle Libre 2 Plus, and Tandem Diabetes Care's t:slim X2 with Dexcom's G7 and Abbott's FreeStyle Libre 2 Plus. Companies like Embecta, Modular Medical, and PharmaSens have submitted innovative patch pump systems to the FDA for potential launch pending approval, showcasing the dynamic landscape of diabetes technology in 2024.

PRODUCT

#cgm

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Feb 28,2024

Nova Scotia announces expanded coverage for insulin pumps and advanced glucose monitoring

The Government of Nova Scotia announced a historic investment to provide better access to diabetes devices such as insulin pumps and glucose monitors for Nova Scotians with diabetes. The province will be investing $5.9 million to fund sensor-based glucose monitoring supplies, and $1.3 million to expand the Nova Scotia Insulin Pump Program by removing the current age cap. Glucose monitoring supplies will be obtained through a new income-based program and through existing pharmacare programs. While Nova Scotians living with either type 1 diabetes (T1D) or type 2 diabetes can access this new program, eligibility requirements will include the need for multiple daily injections of insulin or insulin pumps to manage their diabetes.

#reimbursement

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 27,2024 TOP STORY

Hedia Raises €3M Seed Extension to Expand Digital Health Portfolio

Hedia announced this week it has raised €3 million in a seed extension round strongly supported by existing shareholders and Business Angels. The new capital will enable Hedia's growth strategy and promising digital health product roadmap, continue to scale their Hedia Diabetes Assistant (HDA), as well as launching the Glooko- integrated holistic diabetes management solution later in the year.  Furthermore, the company will leverage its competencies in developing smart AI-enabled algorithms and Software-as-a-Medical Device (SaMD) solutions together with strategic partners within chronic metabolic diseases.

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Feb 28,2024

Omada Health Returns as Sponsor at HLTH 2024

Omada Health is delighted to announce its return as a sponsor at HLTH 2024, the premier event for innovation in healthcare, set to take place at the Venetian in Las Vegas, between October 20-23, 2024. As proud sponsors, Omada Health will have a prominent presence at the conference, offering attendees the opportunity to engage with the company at the company's Booth and in a dedicated Meeting Pod to have 1-on-1 meetings. 

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 27,2024

GLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

Glucotrack announced the selection of Cirtec Medical Corp, the leading medical device solutions provider of implantable therapies, as manufacturer for the implantable Continuous Blood Glucose Monitor (CBGM). The two companies have signed a development agreement for clinical and commercial manufacturing. Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 2+ years, no on-body wearable component and with a once-only calibration event. The company continues to reach significant milestones, such as the recently announced completion of its first preclinical study in animals.

COLLABORATION PARTNERSHIP

#r&d

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 27,2024

Dexcom Announces Upcoming Conference Presentation

DexCom announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5th. The live presentation is scheduled to begin at approximately 8:40 AM EST and will be concurrently webcast.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 28,2024

DARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE

DarioHealth announced that management will participate in the Cowen 44th Annual Healthcare Conference, which is being held March 4-6, 2024, at the Boston Marriott Copley Place in Boston, Massachusetts. Erez Raphael, Chief Executive Officer, and Rick Anderson, President, will participate in a fireside chat on Wednesday, March 6th, from 10:30 – 11:00 AM ET.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 28,2024

Omada Health Takes Center Stage as Gold Level Sponsor at AHIP 2024 Conference

Omada Health is excited to announce its prominent role as a Gold Level Sponsor at the highly anticipated AHIP 2024 conference held in Las Vegas, NV between June 11-13, 2024. The company still has not shared its speaking sessions for this conference.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 13,2024 TOP STORY

TruDoc Acquires Wellthy Therapeutics to Deliver Premier Digital Health Services in the GCC and Expand to India

TruDoc Healthcare, the GCC's premier virtual primary care provider, is thrilled to announce its acquisition of Wellthy Therapeutics. The acquisition of Wellthy Therapeutics' advanced behavioral science and digital therapeutic solutions with TruDoc's extensive virtual and in-home healthcare services marks the dawn of a transformative healthcare era. The synergy of TruDoc and Wellthy Therapeutics will enable insurers, employers, and governments to provide high-quality, individualized care. Integrated services offer connected care, remote monitoring, and instant access to healthcare professionals, all supported by AI and personalized care protocols. 

COLLABORATION MERGERS & ACQUISITION

#product & service

#virtual care

#dtx

View Analyst & Ambassador Comments
Go to original news
Feb 22,2024 TOP STORY

Insulet Reports Full Year 2023 Revenue Increase of 30% and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year

Insulet Corporation announced financial results for the three months and full year ended December 31, 2023. The company's full year 2023 revenue is reported as $1.7 billion, up by 30.0%, or 29.6% in constant currency, compared to $1.3 billion in the prior year, exceeding the guidance range of 26% to 27% in constant currency. Insulet's total Omnipod revenue is reported $1.7 billion in 2023, showing an increase of 33.1%, or 32.7% in constant currency YoY. The Q4 Omnipod revenue was $501.0 million, increased by 36.7%, or 35.4% in constant currency YoY. Recently, the company has also announced the CE Mark of its Omnipod 5's integration with Abbott’s Freestyle Libre 2 Plus sensor.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES